304 related articles for article (PubMed ID: 18381441)
21. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
22. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K; Shin-ya T; Nishio K; Ito F
FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673
[TBL] [Abstract][Full Text] [Related]
23. Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer.
Matsuda Y; Ishiwata T; Yamahatsu K; Kawahara K; Hagio M; Peng WX; Yamamoto T; Nakazawa N; Seya T; Ohaki Y; Naito Z
Cancer Lett; 2011 Oct; 309(2):209-19. PubMed ID: 21745712
[TBL] [Abstract][Full Text] [Related]
24. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells.
Moffa AB; Ethier SP
J Cell Physiol; 2007 Mar; 210(3):720-31. PubMed ID: 17133345
[TBL] [Abstract][Full Text] [Related]
25. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
Saisana M; Griffin SM; May FE
Oncotarget; 2016 Aug; 7(34):54445-54462. PubMed ID: 27437872
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.
Hong L; Han Y; Liu J; Brain L
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):759-65. PubMed ID: 24134151
[TBL] [Abstract][Full Text] [Related]
27. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
28. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.
Tajirika T; Tokumaru Y; Taniguchi K; Sugito N; Matsuhashi N; Futamura M; Yanagihara K; Akao Y; Yoshida K
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987267
[TBL] [Abstract][Full Text] [Related]
29. Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.
Furuta K; Arao T; Sakai K; Kimura H; Nagai T; Tamura D; Aomatsu K; Kudo K; Kaneda H; Fujita Y; Matsumoto K; Yamada Y; Yanagihara K; Sekijima M; Nishio K
Cancer Sci; 2012 Feb; 103(2):221-7. PubMed ID: 22034905
[TBL] [Abstract][Full Text] [Related]
30. Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments.
Kinoshita H; Yashiro M; Fukuoka T; Hasegawa T; Morisaki T; Kasashima H; Masuda G; Noda S; Hirakawa K
Carcinogenesis; 2015 Dec; 36(12):1511-20. PubMed ID: 26385890
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
32. FGFR2 gene amplification and clinicopathological features in gastric cancer.
Matsumoto K; Arao T; Hamaguchi T; Shimada Y; Kato K; Oda I; Taniguchi H; Koizumi F; Yanagihara K; Sasaki H; Nishio K; Yamada Y
Br J Cancer; 2012 Feb; 106(4):727-32. PubMed ID: 22240789
[TBL] [Abstract][Full Text] [Related]
33. FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26.
Katoh M; Katoh M
Int J Oncol; 2003 May; 22(5):1155-9. PubMed ID: 12684685
[TBL] [Abstract][Full Text] [Related]
34. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
35. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
36. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
[TBL] [Abstract][Full Text] [Related]
37. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14.
Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
40. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
